Trillium Therapeutics Inc., of Toronto, presented preclinical and patient case study data for TTI-621 (SIRPa-IgG1 Fc), a CD47-blocking agent, at the EORTC CLTF meeting in London. TTI-621 blocked the CD47 signal in leukemic cells from patients with Sézary syndrome, a form of cutaneous T-cell lymphoma.